June 9, 2021

FDA Approval of a New Treatment: What’s Next for the Alzheimer’s Community?

Thumbnail

FDA Approval of a New Treatment: What’s Next for the Alzheimer’s Community?

About This Episode

The Food and Drug Administration (FDA) has approved aducanumab as a new treatment for early-stage Alzheimer’s disease, and this AlzTalks explores what this means for the Alzheimer’s community.

Host Meryl Comer talked about the drug treatment with Biogen’s Samantha Budd Haeberlein, PhD, SVP, Head of Neurodegeneration Development and Karin Hellsvik, Head, External Communications and Patient Advocacy, and had a conversation about the decision with George Vradenburg, chairman and co-founder of UsAgainstAlzheimer’s; Russ Paulsen, UsA’s chief operating officer; and Jason Resendez, executive director of the UsAgainstAlzheimer’s Center for Brain Health Equity. 

Meryl Comer also spoke about this new drug with advocates Jim and Geri Taylor. Geri, who lives with Alzheimer’s disease, participated in the clinical trial for this therapy.

Press the 'Play' button under the image at left to hear a podcast of the conversation, or watch the full session HERE.

BrainStorm Feed

88

Breaking the Silence: Jay Reinstein’s Mission to End Alzheimer's Stigma

In this episode of BrainStorm, host Meryl Comer talks with Jay Reinstein, a former assistant city manager in North Carolina, about his 12 to15-month journey involving neuropsychological testing and brain scans before being diagnosed with early-onset Alzheimer's at age 57.
LISTEN NOW
87

Agitation and Alzheimer’s with Nancy Treaster

In this episode of BrainStorm Nancy Treaster, a certified caregiving advocate and co-host of The Caregiver's Journey podcast, shares her professional and personal experiences with

LISTEN NOW
86

Muffy Walker, Author of "Memory Weavers"

In this episode of BrainStorm by UsAgainstAlzheimer's Muffy Walker, a psychiatric nurse, founder of the International Bipolar Foundation, and author of the novel "Memory Weavers"

LISTEN NOW